nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—psoriasis—skin cancer	0.443	1	CtDrD
Dexamethasone—PTGS2—skin cancer	0.119	1	CbGaD
Dexamethasone—ABCG2—Vismodegib—skin cancer	0.0336	0.106	CbGbCtD
Dexamethasone—ABCG2—Vemurafenib—skin cancer	0.0265	0.0842	CbGbCtD
Dexamethasone—CYP1B1—Docetaxel—skin cancer	0.0191	0.0607	CbGbCtD
Dexamethasone—CYP1A1—Dacarbazine—skin cancer	0.0188	0.0595	CbGbCtD
Dexamethasone—CYP2C8—Vismodegib—skin cancer	0.0179	0.0567	CbGbCtD
Dexamethasone—ABCG2—Dactinomycin—skin cancer	0.0176	0.0559	CbGbCtD
Dexamethasone—CYP2C19—Vismodegib—skin cancer	0.015	0.0476	CbGbCtD
Dexamethasone—CYP2E1—Dacarbazine—skin cancer	0.0145	0.046	CbGbCtD
Dexamethasone—CYP2A6—Fluorouracil—skin cancer	0.0129	0.0409	CbGbCtD
Dexamethasone—CYP2C9—Vismodegib—skin cancer	0.0125	0.0396	CbGbCtD
Dexamethasone—ABCB1—Vismodegib—skin cancer	0.0121	0.0384	CbGbCtD
Dexamethasone—ABCG2—Fluorouracil—skin cancer	0.0119	0.0378	CbGbCtD
Dexamethasone—CYP3A4—Temozolomide—skin cancer	0.0105	0.0332	CbGbCtD
Dexamethasone—CYP3A4—Imiquimod—skin cancer	0.0105	0.0332	CbGbCtD
Dexamethasone—ABCC2—Docetaxel—skin cancer	0.0101	0.0319	CbGbCtD
Dexamethasone—ABCG2—Docetaxel—skin cancer	0.0091	0.0289	CbGbCtD
Dexamethasone—CYP2D6—Vemurafenib—skin cancer	0.00901	0.0286	CbGbCtD
Dexamethasone—CYP3A4—Vismodegib—skin cancer	0.00725	0.023	CbGbCtD
Dexamethasone—CYP3A7—Docetaxel—skin cancer	0.00672	0.0213	CbGbCtD
Dexamethasone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.00672	0.0213	CbGbCtD
Dexamethasone—ABCB1—Dactinomycin—skin cancer	0.00636	0.0202	CbGbCtD
Dexamethasone—CYP2C8—Fluorouracil—skin cancer	0.00635	0.0201	CbGbCtD
Dexamethasone—CYP3A4—Vemurafenib—skin cancer	0.00573	0.0182	CbGbCtD
Dexamethasone—CYP3A5—Docetaxel—skin cancer	0.00504	0.016	CbGbCtD
Dexamethasone—CYP2C9—Fluorouracil—skin cancer	0.00443	0.014	CbGbCtD
Dexamethasone—ABCB1—Docetaxel—skin cancer	0.00328	0.0104	CbGbCtD
Dexamethasone—CYP3A4—Docetaxel—skin cancer	0.00197	0.00624	CbGbCtD
Dexamethasone—PLA2G1B—blood vessel—skin cancer	0.00137	0.0436	CbGeAlD
Dexamethasone—ANXA1—nerve—skin cancer	0.00133	0.0425	CbGeAlD
Dexamethasone—Fluocinonide—SMO—skin cancer	0.00127	0.866	CrCbGaD
Dexamethasone—ANXA1—hair follicle—skin cancer	0.00111	0.0356	CbGeAlD
Dexamethasone—ANXA1—nipple—skin cancer	0.000755	0.0241	CbGeAlD
Dexamethasone—ANXA1—neck—skin cancer	0.000747	0.0239	CbGeAlD
Dexamethasone—PTGS2—leg—skin cancer	0.000736	0.0235	CbGeAlD
Dexamethasone—PLA2G1B—connective tissue—skin cancer	0.0007	0.0224	CbGeAlD
Dexamethasone—NR0B1—female reproductive system—skin cancer	0.000693	0.0221	CbGeAlD
Dexamethasone—PLA2G1B—epithelium—skin cancer	0.000664	0.0212	CbGeAlD
Dexamethasone—PTGS2—hindlimb—skin cancer	0.000657	0.021	CbGeAlD
Dexamethasone—PGR—blood vessel—skin cancer	0.000628	0.0201	CbGeAlD
Dexamethasone—PTGS2—appendage—skin cancer	0.000564	0.018	CbGeAlD
Dexamethasone—CYP1B1—hair follicle—skin cancer	0.000564	0.018	CbGeAlD
Dexamethasone—CYP1A1—skin epidermis—skin cancer	0.000558	0.0178	CbGeAlD
Dexamethasone—ANXA1—connective tissue—skin cancer	0.000535	0.0171	CbGeAlD
Dexamethasone—ANXA1—epithelium—skin cancer	0.000508	0.0162	CbGeAlD
Dexamethasone—PLA2G1B—female reproductive system—skin cancer	0.000494	0.0158	CbGeAlD
Dexamethasone—NR3C2—nipple—skin cancer	0.000489	0.0156	CbGeAlD
Dexamethasone—ANXA1—skin of body—skin cancer	0.000483	0.0154	CbGeAlD
Dexamethasone—CYP17A1—connective tissue—skin cancer	0.00048	0.0153	CbGeAlD
Dexamethasone—PTGS2—skin epidermis—skin cancer	0.000469	0.015	CbGeAlD
Dexamethasone—NR3C1—nerve—skin cancer	0.000462	0.0147	CbGeAlD
Dexamethasone—PGR—nipple—skin cancer	0.000454	0.0145	CbGeAlD
Dexamethasone—CYP11A1—connective tissue—skin cancer	0.000446	0.0143	CbGeAlD
Dexamethasone—ANXA1—mammalian vulva—skin cancer	0.000441	0.0141	CbGeAlD
Dexamethasone—PLA2G1B—head—skin cancer	0.000412	0.0132	CbGeAlD
Dexamethasone—ANXA1—lymphoid tissue—skin cancer	0.000391	0.0125	CbGeAlD
Dexamethasone—ANXA1—female reproductive system—skin cancer	0.000377	0.0121	CbGeAlD
Dexamethasone—NR3C2—connective tissue—skin cancer	0.000347	0.0111	CbGeAlD
Dexamethasone—PTGS2—endothelium—skin cancer	0.00034	0.0109	CbGeAlD
Dexamethasone—CYP17A1—female reproductive system—skin cancer	0.000338	0.0108	CbGeAlD
Dexamethasone—PGR—connective tissue—skin cancer	0.000322	0.0103	CbGeAlD
Dexamethasone—ANXA1—head—skin cancer	0.000315	0.0101	CbGeAlD
Dexamethasone—CYP11A1—female reproductive system—skin cancer	0.000315	0.0101	CbGeAlD
Dexamethasone—PTGS2—blood vessel—skin cancer	0.000314	0.01	CbGeAlD
Dexamethasone—PGR—epithelium—skin cancer	0.000306	0.00977	CbGeAlD
Dexamethasone—CYP19A1—connective tissue—skin cancer	0.00029	0.00926	CbGeAlD
Dexamethasone—NR3C2—mammalian vulva—skin cancer	0.000285	0.00912	CbGeAlD
Dexamethasone—CYP17A1—head—skin cancer	0.000283	0.00903	CbGeAlD
Dexamethasone—CYP1B1—connective tissue—skin cancer	0.000271	0.00866	CbGeAlD
Dexamethasone—CYP1A1—nipple—skin cancer	0.00027	0.00863	CbGeAlD
Dexamethasone—CYP11A1—head—skin cancer	0.000263	0.0084	CbGeAlD
Dexamethasone—NR3C1—nipple—skin cancer	0.000262	0.00837	CbGeAlD
Dexamethasone—NR3C1—neck—skin cancer	0.000259	0.00829	CbGeAlD
Dexamethasone—CYP1B1—skin of body—skin cancer	0.000245	0.00782	CbGeAlD
Dexamethasone—NR3C2—female reproductive system—skin cancer	0.000244	0.00781	CbGeAlD
Dexamethasone—PGR—lymphoid tissue—skin cancer	0.000236	0.00752	CbGeAlD
Dexamethasone—PGR—female reproductive system—skin cancer	0.000227	0.00726	CbGeAlD
Dexamethasone—ANXA1—lymph node—skin cancer	0.000221	0.00705	CbGeAlD
Dexamethasone—CYP19A1—female reproductive system—skin cancer	0.000204	0.00653	CbGeAlD
Dexamethasone—NR3C2—head—skin cancer	0.000204	0.00652	CbGeAlD
Dexamethasone—CYP1B1—lymphoid tissue—skin cancer	0.000198	0.00633	CbGeAlD
Dexamethasone—CYP17A1—lymph node—skin cancer	0.000198	0.00632	CbGeAlD
Dexamethasone—ABCC2—female reproductive system—skin cancer	0.000195	0.00623	CbGeAlD
Dexamethasone—ABCB1—blood vessel—skin cancer	0.000194	0.0062	CbGeAlD
Dexamethasone—CYP1B1—female reproductive system—skin cancer	0.000191	0.00611	CbGeAlD
Dexamethasone—PGR—head—skin cancer	0.00019	0.00606	CbGeAlD
Dexamethasone—NR3C1—connective tissue—skin cancer	0.000186	0.00594	CbGeAlD
Dexamethasone—CYP11A1—lymph node—skin cancer	0.000184	0.00588	CbGeAlD
Dexamethasone—CYP1A1—epithelium—skin cancer	0.000182	0.00581	CbGeAlD
Dexamethasone—NR3C1—epithelium—skin cancer	0.000177	0.00564	CbGeAlD
Dexamethasone—SLCO1A2—head—skin cancer	0.000175	0.00559	CbGeAlD
Dexamethasone—CYP1A1—skin of body—skin cancer	0.000173	0.00553	CbGeAlD
Dexamethasone—CYP19A1—head—skin cancer	0.000171	0.00546	CbGeAlD
Dexamethasone—CYP2B6—skin of body—skin cancer	0.000168	0.00537	CbGeAlD
Dexamethasone—NR3C1—skin of body—skin cancer	0.000168	0.00536	CbGeAlD
Dexamethasone—Skin exfoliation—Docetaxel—skin cancer	0.000167	0.00236	CcSEcCtD
Dexamethasone—ABCG2—mammalian vulva—skin cancer	0.000166	0.00531	CbGeAlD
Dexamethasone—Convulsion—Imiquimod—skin cancer	0.000166	0.00235	CcSEcCtD
Dexamethasone—Fluid retention—Docetaxel—skin cancer	0.000166	0.00235	CcSEcCtD
Dexamethasone—Hypertension—Imiquimod—skin cancer	0.000165	0.00234	CcSEcCtD
Dexamethasone—Neuropathy—Docetaxel—skin cancer	0.000164	0.00232	CcSEcCtD
Dexamethasone—Myalgia—Imiquimod—skin cancer	0.000163	0.00231	CcSEcCtD
Dexamethasone—Anxiety—Imiquimod—skin cancer	0.000163	0.0023	CcSEcCtD
Dexamethasone—Discomfort—Imiquimod—skin cancer	0.000161	0.00228	CcSEcCtD
Dexamethasone—Dry skin—Fluorouracil—skin cancer	0.000161	0.00228	CcSEcCtD
Dexamethasone—PTGS2—connective tissue—skin cancer	0.000161	0.00514	CbGeAlD
Dexamethasone—Sweating increased—Temozolomide—skin cancer	0.000161	0.00227	CcSEcCtD
Dexamethasone—CYP1B1—head—skin cancer	0.00016	0.0051	CbGeAlD
Dexamethasone—Oesophagitis—Docetaxel—skin cancer	0.00016	0.00226	CcSEcCtD
Dexamethasone—Decreased appetite—Vemurafenib—skin cancer	0.000159	0.00226	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000158	0.00224	CcSEcCtD
Dexamethasone—Fatigue—Vemurafenib—skin cancer	0.000158	0.00224	CcSEcCtD
Dexamethasone—CYP1A1—mammalian vulva—skin cancer	0.000158	0.00504	CbGeAlD
Dexamethasone—Haemoglobin—Bleomycin—skin cancer	0.000157	0.00223	CcSEcCtD
Dexamethasone—Oedema—Imiquimod—skin cancer	0.000156	0.00222	CcSEcCtD
Dexamethasone—Haemorrhage—Bleomycin—skin cancer	0.000156	0.00222	CcSEcCtD
Dexamethasone—Pulmonary oedema—Docetaxel—skin cancer	0.000155	0.0022	CcSEcCtD
Dexamethasone—Infection—Imiquimod—skin cancer	0.000155	0.0022	CcSEcCtD
Dexamethasone—Muscular weakness—Fluorouracil—skin cancer	0.000155	0.0022	CcSEcCtD
Dexamethasone—Shock—Imiquimod—skin cancer	0.000154	0.00218	CcSEcCtD
Dexamethasone—Nervous system disorder—Imiquimod—skin cancer	0.000153	0.00217	CcSEcCtD
Dexamethasone—NR3C1—mammalian vulva—skin cancer	0.000153	0.00489	CbGeAlD
Dexamethasone—PTGS2—epithelium—skin cancer	0.000153	0.00488	CbGeAlD
Dexamethasone—Tachycardia—Imiquimod—skin cancer	0.000153	0.00216	CcSEcCtD
Dexamethasone—Hyperhidrosis—Imiquimod—skin cancer	0.000151	0.00214	CcSEcCtD
Dexamethasone—Weight increased—Temozolomide—skin cancer	0.00015	0.00213	CcSEcCtD
Dexamethasone—Weight decreased—Temozolomide—skin cancer	0.000149	0.00211	CcSEcCtD
Dexamethasone—Anorexia—Imiquimod—skin cancer	0.000149	0.00211	CcSEcCtD
Dexamethasone—Hyperglycaemia—Temozolomide—skin cancer	0.000149	0.00211	CcSEcCtD
Dexamethasone—Thrombophlebitis—Docetaxel—skin cancer	0.000146	0.00208	CcSEcCtD
Dexamethasone—CYP2C8—female reproductive system—skin cancer	0.000146	0.00468	CbGeAlD
Dexamethasone—PTGS2—skin of body—skin cancer	0.000145	0.00464	CbGeAlD
Dexamethasone—Body temperature increased—Vemurafenib—skin cancer	0.000145	0.00205	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Temozolomide—skin cancer	0.000144	0.00204	CcSEcCtD
Dexamethasone—NR3C2—lymph node—skin cancer	0.000143	0.00457	CbGeAlD
Dexamethasone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000142	0.00202	CcSEcCtD
Dexamethasone—Insomnia—Imiquimod—skin cancer	0.000141	0.002	CcSEcCtD
Dexamethasone—Paraesthesia—Imiquimod—skin cancer	0.00014	0.00199	CcSEcCtD
Dexamethasone—Cardiac failure congestive—Docetaxel—skin cancer	0.00014	0.00198	CcSEcCtD
Dexamethasone—Alopecia—Bleomycin—skin cancer	0.000138	0.00196	CcSEcCtD
Dexamethasone—Dyspepsia—Imiquimod—skin cancer	0.000138	0.00195	CcSEcCtD
Dexamethasone—CYP2B6—lymphoid tissue—skin cancer	0.000136	0.00435	CbGeAlD
Dexamethasone—Erythema—Bleomycin—skin cancer	0.000136	0.00193	CcSEcCtD
Dexamethasone—NR3C1—lymphoid tissue—skin cancer	0.000136	0.00434	CbGeAlD
Dexamethasone—Decreased appetite—Imiquimod—skin cancer	0.000136	0.00193	CcSEcCtD
Dexamethasone—CYP1A1—female reproductive system—skin cancer	0.000135	0.00432	CbGeAlD
Dexamethasone—Gastrointestinal disorder—Imiquimod—skin cancer	0.000135	0.00191	CcSEcCtD
Dexamethasone—Fatigue—Imiquimod—skin cancer	0.000135	0.00191	CcSEcCtD
Dexamethasone—Visual disturbance—Docetaxel—skin cancer	0.000134	0.0019	CcSEcCtD
Dexamethasone—Pain—Imiquimod—skin cancer	0.000134	0.0019	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Fluorouracil—skin cancer	0.000133	0.00189	CcSEcCtD
Dexamethasone—PGR—lymph node—skin cancer	0.000133	0.00425	CbGeAlD
Dexamethasone—Neuropathy peripheral—Fluorouracil—skin cancer	0.000133	0.00188	CcSEcCtD
Dexamethasone—Myocardial infarction—Fluorouracil—skin cancer	0.000133	0.00188	CcSEcCtD
Dexamethasone—Dermatitis bullous—Docetaxel—skin cancer	0.000133	0.00188	CcSEcCtD
Dexamethasone—Haemoglobin—Temozolomide—skin cancer	0.000133	0.00188	CcSEcCtD
Dexamethasone—Haemorrhage—Temozolomide—skin cancer	0.000132	0.00187	CcSEcCtD
Dexamethasone—Conjunctivitis—Fluorouracil—skin cancer	0.000132	0.00186	CcSEcCtD
Dexamethasone—Asthenia—Vemurafenib—skin cancer	0.000132	0.00186	CcSEcCtD
Dexamethasone—CYP2B6—female reproductive system—skin cancer	0.000131	0.00419	CbGeAlD
Dexamethasone—Hallucination—Temozolomide—skin cancer	0.000131	0.00186	CcSEcCtD
Dexamethasone—NR3C1—female reproductive system—skin cancer	0.000131	0.00419	CbGeAlD
Dexamethasone—CYP2C9—female reproductive system—skin cancer	0.00013	0.00415	CbGeAlD
Dexamethasone—Cardiac failure—Docetaxel—skin cancer	0.00013	0.00184	CcSEcCtD
Dexamethasone—Pruritus—Vemurafenib—skin cancer	0.00013	0.00184	CcSEcCtD
Dexamethasone—Lethargy—Docetaxel—skin cancer	0.000129	0.00183	CcSEcCtD
Dexamethasone—Alopecia—Dactinomycin—skin cancer	0.000129	0.00183	CcSEcCtD
Dexamethasone—Feeling abnormal—Imiquimod—skin cancer	0.000129	0.00183	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Imiquimod—skin cancer	0.000128	0.00181	CcSEcCtD
Dexamethasone—CYP2E1—lymphoid tissue—skin cancer	0.000128	0.00408	CbGeAlD
Dexamethasone—Visual impairment—Temozolomide—skin cancer	0.000127	0.0018	CcSEcCtD
Dexamethasone—Erythema—Dactinomycin—skin cancer	0.000127	0.0018	CcSEcCtD
Dexamethasone—Ill-defined disorder—Bleomycin—skin cancer	0.000126	0.00179	CcSEcCtD
Dexamethasone—Diarrhoea—Vemurafenib—skin cancer	0.000125	0.00178	CcSEcCtD
Dexamethasone—Migraine—Docetaxel—skin cancer	0.000125	0.00177	CcSEcCtD
Dexamethasone—Urticaria—Imiquimod—skin cancer	0.000124	0.00176	CcSEcCtD
Dexamethasone—Body temperature increased—Imiquimod—skin cancer	0.000124	0.00175	CcSEcCtD
Dexamethasone—Abdominal pain—Imiquimod—skin cancer	0.000124	0.00175	CcSEcCtD
Dexamethasone—Eye disorder—Temozolomide—skin cancer	0.000123	0.00175	CcSEcCtD
Dexamethasone—CYP2E1—female reproductive system—skin cancer	0.000123	0.00394	CbGeAlD
Dexamethasone—Malaise—Bleomycin—skin cancer	0.000123	0.00174	CcSEcCtD
Dexamethasone—Haemoglobin—Fluorouracil—skin cancer	0.000122	0.00173	CcSEcCtD
Dexamethasone—Haemorrhage—Fluorouracil—skin cancer	0.000122	0.00172	CcSEcCtD
Dexamethasone—Dizziness—Vemurafenib—skin cancer	0.000121	0.00172	CcSEcCtD
Dexamethasone—Angiopathy—Temozolomide—skin cancer	0.00012	0.0017	CcSEcCtD
Dexamethasone—CYP19A1—lymph node—skin cancer	0.00012	0.00382	CbGeAlD
Dexamethasone—Ill-defined disorder—Dactinomycin—skin cancer	0.000118	0.00167	CcSEcCtD
Dexamethasone—PTGS2—lymphoid tissue—skin cancer	0.000118	0.00376	CbGeAlD
Dexamethasone—Vomiting—Vemurafenib—skin cancer	0.000117	0.00165	CcSEcCtD
Dexamethasone—Alopecia—Temozolomide—skin cancer	0.000117	0.00165	CcSEcCtD
Dexamethasone—Dry skin—Docetaxel—skin cancer	0.000116	0.00165	CcSEcCtD
Dexamethasone—Myalgia—Bleomycin—skin cancer	0.000116	0.00164	CcSEcCtD
Dexamethasone—Rash—Vemurafenib—skin cancer	0.000116	0.00164	CcSEcCtD
Dexamethasone—Dermatitis—Vemurafenib—skin cancer	0.000116	0.00164	CcSEcCtD
Dexamethasone—Headache—Vemurafenib—skin cancer	0.000115	0.00163	CcSEcCtD
Dexamethasone—Erythema—Temozolomide—skin cancer	0.000115	0.00163	CcSEcCtD
Dexamethasone—Discomfort—Bleomycin—skin cancer	0.000114	0.00162	CcSEcCtD
Dexamethasone—Malaise—Dactinomycin—skin cancer	0.000114	0.00162	CcSEcCtD
Dexamethasone—ABCC2—lymph node—skin cancer	0.000114	0.00365	CbGeAlD
Dexamethasone—PTGS2—female reproductive system—skin cancer	0.000113	0.00362	CbGeAlD
Dexamethasone—CYP1A1—head—skin cancer	0.000113	0.00361	CbGeAlD
Dexamethasone—Asthenia—Imiquimod—skin cancer	0.000112	0.00159	CcSEcCtD
Dexamethasone—CYP1B1—lymph node—skin cancer	0.000112	0.00357	CbGeAlD
Dexamethasone—Oedema—Bleomycin—skin cancer	0.000111	0.00157	CcSEcCtD
Dexamethasone—Anaphylactic shock—Bleomycin—skin cancer	0.000111	0.00157	CcSEcCtD
Dexamethasone—Pruritus—Imiquimod—skin cancer	0.000111	0.00157	CcSEcCtD
Dexamethasone—Infection—Bleomycin—skin cancer	0.00011	0.00156	CcSEcCtD
Dexamethasone—CYP2B6—head—skin cancer	0.00011	0.0035	CbGeAlD
Dexamethasone—NR3C1—head—skin cancer	0.00011	0.0035	CbGeAlD
Dexamethasone—Nausea—Vemurafenib—skin cancer	0.000109	0.00154	CcSEcCtD
Dexamethasone—Thrombocytopenia—Bleomycin—skin cancer	0.000109	0.00154	CcSEcCtD
Dexamethasone—Arrhythmia—Fluorouracil—skin cancer	0.000109	0.00154	CcSEcCtD
Dexamethasone—Myalgia—Dactinomycin—skin cancer	0.000108	0.00153	CcSEcCtD
Dexamethasone—Triamcinolone—PTGS2—skin cancer	0.000108	0.0736	CrCbGaD
Dexamethasone—Alopecia—Fluorouracil—skin cancer	0.000107	0.00152	CcSEcCtD
Dexamethasone—Diarrhoea—Imiquimod—skin cancer	0.000107	0.00152	CcSEcCtD
Dexamethasone—Discomfort—Dactinomycin—skin cancer	0.000107	0.00151	CcSEcCtD
Dexamethasone—Ill-defined disorder—Temozolomide—skin cancer	0.000107	0.00151	CcSEcCtD
Dexamethasone—Anorexia—Bleomycin—skin cancer	0.000106	0.0015	CcSEcCtD
Dexamethasone—Erythema—Fluorouracil—skin cancer	0.000106	0.0015	CcSEcCtD
Dexamethasone—Angioedema—Temozolomide—skin cancer	0.000105	0.00149	CcSEcCtD
Dexamethasone—Hypotension—Bleomycin—skin cancer	0.000104	0.00147	CcSEcCtD
Dexamethasone—Oedema—Dactinomycin—skin cancer	0.000104	0.00147	CcSEcCtD
Dexamethasone—Malaise—Temozolomide—skin cancer	0.000104	0.00147	CcSEcCtD
Dexamethasone—Dizziness—Imiquimod—skin cancer	0.000103	0.00147	CcSEcCtD
Dexamethasone—Vertigo—Temozolomide—skin cancer	0.000103	0.00146	CcSEcCtD
Dexamethasone—CYP2E1—head—skin cancer	0.000103	0.00329	CbGeAlD
Dexamethasone—Infection—Dactinomycin—skin cancer	0.000103	0.00146	CcSEcCtD
Dexamethasone—Thrombocytopenia—Dactinomycin—skin cancer	0.000101	0.00144	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000101	0.00143	CcSEcCtD
Dexamethasone—Paraesthesia—Bleomycin—skin cancer	9.98e-05	0.00141	CcSEcCtD
Dexamethasone—Weight increased—Docetaxel—skin cancer	9.97e-05	0.00141	CcSEcCtD
Dexamethasone—Convulsion—Temozolomide—skin cancer	9.95e-05	0.00141	CcSEcCtD
Dexamethasone—Vomiting—Imiquimod—skin cancer	9.94e-05	0.00141	CcSEcCtD
Dexamethasone—CYP3A4—female reproductive system—skin cancer	9.92e-05	0.00317	CbGeAlD
Dexamethasone—Weight decreased—Docetaxel—skin cancer	9.91e-05	0.00141	CcSEcCtD
Dexamethasone—Hypertension—Temozolomide—skin cancer	9.91e-05	0.0014	CcSEcCtD
Dexamethasone—Anorexia—Dactinomycin—skin cancer	9.88e-05	0.0014	CcSEcCtD
Dexamethasone—Rash—Imiquimod—skin cancer	9.86e-05	0.0014	CcSEcCtD
Dexamethasone—Dermatitis—Imiquimod—skin cancer	9.85e-05	0.0014	CcSEcCtD
Dexamethasone—Headache—Imiquimod—skin cancer	9.8e-05	0.00139	CcSEcCtD
Dexamethasone—Myalgia—Temozolomide—skin cancer	9.78e-05	0.00139	CcSEcCtD
Dexamethasone—CYP2D6—female reproductive system—skin cancer	9.76e-05	0.00312	CbGeAlD
Dexamethasone—Anxiety—Temozolomide—skin cancer	9.74e-05	0.00138	CcSEcCtD
Dexamethasone—Discomfort—Temozolomide—skin cancer	9.66e-05	0.00137	CcSEcCtD
Dexamethasone—Decreased appetite—Bleomycin—skin cancer	9.66e-05	0.00137	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Docetaxel—skin cancer	9.63e-05	0.00137	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Docetaxel—skin cancer	9.58e-05	0.00136	CcSEcCtD
Dexamethasone—Myocardial infarction—Docetaxel—skin cancer	9.58e-05	0.00136	CcSEcCtD
Dexamethasone—Pain—Bleomycin—skin cancer	9.5e-05	0.00135	CcSEcCtD
Dexamethasone—Conjunctivitis—Docetaxel—skin cancer	9.5e-05	0.00135	CcSEcCtD
Dexamethasone—PTGS2—head—skin cancer	9.48e-05	0.00303	CbGeAlD
Dexamethasone—ABCB1—epithelium—skin cancer	9.45e-05	0.00302	CbGeAlD
Dexamethasone—Musculoskeletal discomfort—Dactinomycin—skin cancer	9.44e-05	0.00134	CcSEcCtD
Dexamethasone—Anaphylactic shock—Temozolomide—skin cancer	9.37e-05	0.00133	CcSEcCtD
Dexamethasone—Oedema—Temozolomide—skin cancer	9.37e-05	0.00133	CcSEcCtD
Dexamethasone—Infection—Temozolomide—skin cancer	9.31e-05	0.00132	CcSEcCtD
Dexamethasone—Nausea—Imiquimod—skin cancer	9.29e-05	0.00132	CcSEcCtD
Dexamethasone—Nervous system disorder—Temozolomide—skin cancer	9.19e-05	0.0013	CcSEcCtD
Dexamethasone—Thrombocytopenia—Temozolomide—skin cancer	9.18e-05	0.0013	CcSEcCtD
Dexamethasone—Convulsion—Fluorouracil—skin cancer	9.17e-05	0.0013	CcSEcCtD
Dexamethasone—Feeling abnormal—Bleomycin—skin cancer	9.15e-05	0.0013	CcSEcCtD
Dexamethasone—Hyperhidrosis—Temozolomide—skin cancer	9.06e-05	0.00128	CcSEcCtD
Dexamethasone—Myalgia—Fluorouracil—skin cancer	9.01e-05	0.00128	CcSEcCtD
Dexamethasone—Decreased appetite—Dactinomycin—skin cancer	9.01e-05	0.00128	CcSEcCtD
Dexamethasone—Fatigue—Dactinomycin—skin cancer	8.93e-05	0.00127	CcSEcCtD
Dexamethasone—Anorexia—Temozolomide—skin cancer	8.93e-05	0.00127	CcSEcCtD
Dexamethasone—Discomfort—Fluorouracil—skin cancer	8.9e-05	0.00126	CcSEcCtD
Dexamethasone—Pain—Dactinomycin—skin cancer	8.86e-05	0.00126	CcSEcCtD
Dexamethasone—Urticaria—Bleomycin—skin cancer	8.83e-05	0.00125	CcSEcCtD
Dexamethasone—Haemoglobin—Docetaxel—skin cancer	8.82e-05	0.00125	CcSEcCtD
Dexamethasone—Betamethasone—PTGS2—skin cancer	8.81e-05	0.0603	CrCbGaD
Dexamethasone—Body temperature increased—Bleomycin—skin cancer	8.78e-05	0.00124	CcSEcCtD
Dexamethasone—Haemorrhage—Docetaxel—skin cancer	8.77e-05	0.00124	CcSEcCtD
Dexamethasone—Anaphylactic shock—Fluorouracil—skin cancer	8.63e-05	0.00122	CcSEcCtD
Dexamethasone—Oedema—Fluorouracil—skin cancer	8.63e-05	0.00122	CcSEcCtD
Dexamethasone—Infection—Fluorouracil—skin cancer	8.58e-05	0.00122	CcSEcCtD
Dexamethasone—Feeling abnormal—Dactinomycin—skin cancer	8.54e-05	0.00121	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Temozolomide—skin cancer	8.54e-05	0.00121	CcSEcCtD
Dexamethasone—Insomnia—Temozolomide—skin cancer	8.48e-05	0.0012	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Dactinomycin—skin cancer	8.47e-05	0.0012	CcSEcCtD
Dexamethasone—Nervous system disorder—Fluorouracil—skin cancer	8.47e-05	0.0012	CcSEcCtD
Dexamethasone—Thrombocytopenia—Fluorouracil—skin cancer	8.45e-05	0.0012	CcSEcCtD
Dexamethasone—Visual impairment—Docetaxel—skin cancer	8.45e-05	0.0012	CcSEcCtD
Dexamethasone—Tachycardia—Fluorouracil—skin cancer	8.43e-05	0.00119	CcSEcCtD
Dexamethasone—Paraesthesia—Temozolomide—skin cancer	8.41e-05	0.00119	CcSEcCtD
Dexamethasone—ABCG2—lymph node—skin cancer	8.33e-05	0.00266	CbGeAlD
Dexamethasone—Dyspepsia—Temozolomide—skin cancer	8.25e-05	0.00117	CcSEcCtD
Dexamethasone—Anorexia—Fluorouracil—skin cancer	8.23e-05	0.00117	CcSEcCtD
Dexamethasone—Eye disorder—Docetaxel—skin cancer	8.2e-05	0.00116	CcSEcCtD
Dexamethasone—ABCB1—mammalian vulva—skin cancer	8.2e-05	0.00262	CbGeAlD
Dexamethasone—Body temperature increased—Dactinomycin—skin cancer	8.19e-05	0.00116	CcSEcCtD
Dexamethasone—Abdominal pain—Dactinomycin—skin cancer	8.19e-05	0.00116	CcSEcCtD
Dexamethasone—CYP2D6—head—skin cancer	8.15e-05	0.0026	CbGeAlD
Dexamethasone—Decreased appetite—Temozolomide—skin cancer	8.15e-05	0.00115	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Temozolomide—skin cancer	8.09e-05	0.00115	CcSEcCtD
Dexamethasone—Fatigue—Temozolomide—skin cancer	8.08e-05	0.00114	CcSEcCtD
Dexamethasone—Hypotension—Fluorouracil—skin cancer	8.07e-05	0.00114	CcSEcCtD
Dexamethasone—Pain—Temozolomide—skin cancer	8.01e-05	0.00114	CcSEcCtD
Dexamethasone—Asthenia—Bleomycin—skin cancer	7.97e-05	0.00113	CcSEcCtD
Dexamethasone—Angiopathy—Docetaxel—skin cancer	7.96e-05	0.00113	CcSEcCtD
Dexamethasone—CYP1A1—lymph node—skin cancer	7.91e-05	0.00252	CbGeAlD
Dexamethasone—Musculoskeletal discomfort—Fluorouracil—skin cancer	7.87e-05	0.00111	CcSEcCtD
Dexamethasone—Pruritus—Bleomycin—skin cancer	7.86e-05	0.00111	CcSEcCtD
Dexamethasone—Arrhythmia—Docetaxel—skin cancer	7.84e-05	0.00111	CcSEcCtD
Dexamethasone—Insomnia—Fluorouracil—skin cancer	7.81e-05	0.00111	CcSEcCtD
Dexamethasone—Paraesthesia—Fluorouracil—skin cancer	7.75e-05	0.0011	CcSEcCtD
Dexamethasone—Alopecia—Docetaxel—skin cancer	7.75e-05	0.0011	CcSEcCtD
Dexamethasone—Feeling abnormal—Temozolomide—skin cancer	7.72e-05	0.00109	CcSEcCtD
Dexamethasone—NR3C1—lymph node—skin cancer	7.67e-05	0.00245	CbGeAlD
Dexamethasone—Gastrointestinal pain—Temozolomide—skin cancer	7.66e-05	0.00109	CcSEcCtD
Dexamethasone—Erythema—Docetaxel—skin cancer	7.64e-05	0.00108	CcSEcCtD
Dexamethasone—Dyspepsia—Fluorouracil—skin cancer	7.6e-05	0.00108	CcSEcCtD
Dexamethasone—Decreased appetite—Fluorouracil—skin cancer	7.51e-05	0.00106	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Fluorouracil—skin cancer	7.45e-05	0.00106	CcSEcCtD
Dexamethasone—Urticaria—Temozolomide—skin cancer	7.44e-05	0.00105	CcSEcCtD
Dexamethasone—Asthenia—Dactinomycin—skin cancer	7.43e-05	0.00105	CcSEcCtD
Dexamethasone—Abdominal pain—Temozolomide—skin cancer	7.41e-05	0.00105	CcSEcCtD
Dexamethasone—Body temperature increased—Temozolomide—skin cancer	7.41e-05	0.00105	CcSEcCtD
Dexamethasone—Pain—Fluorouracil—skin cancer	7.38e-05	0.00105	CcSEcCtD
Dexamethasone—ABCB1—lymphoid tissue—skin cancer	7.28e-05	0.00232	CbGeAlD
Dexamethasone—Feeling abnormal—Fluorouracil—skin cancer	7.11e-05	0.00101	CcSEcCtD
Dexamethasone—Diarrhoea—Dactinomycin—skin cancer	7.09e-05	0.001	CcSEcCtD
Dexamethasone—Vomiting—Bleomycin—skin cancer	7.06e-05	0.001	CcSEcCtD
Dexamethasone—ABCB1—female reproductive system—skin cancer	7.02e-05	0.00224	CbGeAlD
Dexamethasone—Rash—Bleomycin—skin cancer	7e-05	0.000993	CcSEcCtD
Dexamethasone—Dermatitis—Bleomycin—skin cancer	7e-05	0.000992	CcSEcCtD
Dexamethasone—Urticaria—Fluorouracil—skin cancer	6.86e-05	0.000972	CcSEcCtD
Dexamethasone—Syncope—Docetaxel—skin cancer	6.85e-05	0.00097	CcSEcCtD
Dexamethasone—Body temperature increased—Fluorouracil—skin cancer	6.83e-05	0.000967	CcSEcCtD
Dexamethasone—Asthenia—Temozolomide—skin cancer	6.72e-05	0.000953	CcSEcCtD
Dexamethasone—Loss of consciousness—Docetaxel—skin cancer	6.71e-05	0.000951	CcSEcCtD
Dexamethasone—PTGS2—lymph node—skin cancer	6.64e-05	0.00212	CbGeAlD
Dexamethasone—Pruritus—Temozolomide—skin cancer	6.63e-05	0.00094	CcSEcCtD
Dexamethasone—Convulsion—Docetaxel—skin cancer	6.62e-05	0.000938	CcSEcCtD
Dexamethasone—Nausea—Bleomycin—skin cancer	6.6e-05	0.000935	CcSEcCtD
Dexamethasone—Hypertension—Docetaxel—skin cancer	6.59e-05	0.000934	CcSEcCtD
Dexamethasone—Vomiting—Dactinomycin—skin cancer	6.59e-05	0.000934	CcSEcCtD
Dexamethasone—Rash—Dactinomycin—skin cancer	6.53e-05	0.000926	CcSEcCtD
Dexamethasone—Myalgia—Docetaxel—skin cancer	6.5e-05	0.000921	CcSEcCtD
Dexamethasone—Diarrhoea—Temozolomide—skin cancer	6.41e-05	0.000909	CcSEcCtD
Dexamethasone—Anaphylactic shock—Docetaxel—skin cancer	6.23e-05	0.000883	CcSEcCtD
Dexamethasone—Oedema—Docetaxel—skin cancer	6.23e-05	0.000883	CcSEcCtD
Dexamethasone—Dizziness—Temozolomide—skin cancer	6.2e-05	0.000878	CcSEcCtD
Dexamethasone—Infection—Docetaxel—skin cancer	6.19e-05	0.000877	CcSEcCtD
Dexamethasone—Nausea—Dactinomycin—skin cancer	6.15e-05	0.000872	CcSEcCtD
Dexamethasone—Shock—Docetaxel—skin cancer	6.13e-05	0.000869	CcSEcCtD
Dexamethasone—Nervous system disorder—Docetaxel—skin cancer	6.11e-05	0.000866	CcSEcCtD
Dexamethasone—Pruritus—Fluorouracil—skin cancer	6.11e-05	0.000866	CcSEcCtD
Dexamethasone—Thrombocytopenia—Docetaxel—skin cancer	6.1e-05	0.000865	CcSEcCtD
Dexamethasone—Tachycardia—Docetaxel—skin cancer	6.08e-05	0.000862	CcSEcCtD
Dexamethasone—Vomiting—Temozolomide—skin cancer	5.96e-05	0.000844	CcSEcCtD
Dexamethasone—Anorexia—Docetaxel—skin cancer	5.94e-05	0.000842	CcSEcCtD
Dexamethasone—Rash—Temozolomide—skin cancer	5.91e-05	0.000837	CcSEcCtD
Dexamethasone—Diarrhoea—Fluorouracil—skin cancer	5.91e-05	0.000837	CcSEcCtD
Dexamethasone—Dermatitis—Temozolomide—skin cancer	5.9e-05	0.000837	CcSEcCtD
Dexamethasone—Headache—Temozolomide—skin cancer	5.87e-05	0.000832	CcSEcCtD
Dexamethasone—ABCB1—head—skin cancer	5.86e-05	0.00187	CbGeAlD
Dexamethasone—Hypotension—Docetaxel—skin cancer	5.82e-05	0.000825	CcSEcCtD
Dexamethasone—Dizziness—Fluorouracil—skin cancer	5.71e-05	0.000809	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Docetaxel—skin cancer	5.68e-05	0.000805	CcSEcCtD
Dexamethasone—Insomnia—Docetaxel—skin cancer	5.64e-05	0.000799	CcSEcCtD
Dexamethasone—Paraesthesia—Docetaxel—skin cancer	5.6e-05	0.000793	CcSEcCtD
Dexamethasone—Nausea—Temozolomide—skin cancer	5.57e-05	0.000789	CcSEcCtD
Dexamethasone—Vomiting—Fluorouracil—skin cancer	5.49e-05	0.000778	CcSEcCtD
Dexamethasone—Dyspepsia—Docetaxel—skin cancer	5.49e-05	0.000777	CcSEcCtD
Dexamethasone—Rash—Fluorouracil—skin cancer	5.44e-05	0.000771	CcSEcCtD
Dexamethasone—Dermatitis—Fluorouracil—skin cancer	5.44e-05	0.000771	CcSEcCtD
Dexamethasone—Decreased appetite—Docetaxel—skin cancer	5.42e-05	0.000768	CcSEcCtD
Dexamethasone—Headache—Fluorouracil—skin cancer	5.41e-05	0.000767	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Docetaxel—skin cancer	5.38e-05	0.000762	CcSEcCtD
Dexamethasone—Fatigue—Docetaxel—skin cancer	5.37e-05	0.000761	CcSEcCtD
Dexamethasone—Pain—Docetaxel—skin cancer	5.33e-05	0.000755	CcSEcCtD
Dexamethasone—Feeling abnormal—Docetaxel—skin cancer	5.14e-05	0.000728	CcSEcCtD
Dexamethasone—Nausea—Fluorouracil—skin cancer	5.13e-05	0.000727	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Docetaxel—skin cancer	5.1e-05	0.000722	CcSEcCtD
Dexamethasone—Abdominal pain—Docetaxel—skin cancer	4.93e-05	0.000698	CcSEcCtD
Dexamethasone—Body temperature increased—Docetaxel—skin cancer	4.93e-05	0.000698	CcSEcCtD
Dexamethasone—Asthenia—Docetaxel—skin cancer	4.47e-05	0.000634	CcSEcCtD
Dexamethasone—Pruritus—Docetaxel—skin cancer	4.41e-05	0.000625	CcSEcCtD
Dexamethasone—Diarrhoea—Docetaxel—skin cancer	4.26e-05	0.000604	CcSEcCtD
Dexamethasone—Dizziness—Docetaxel—skin cancer	4.12e-05	0.000584	CcSEcCtD
Dexamethasone—ABCB1—lymph node—skin cancer	4.11e-05	0.00131	CbGeAlD
Dexamethasone—Vomiting—Docetaxel—skin cancer	3.96e-05	0.000562	CcSEcCtD
Dexamethasone—Rash—Docetaxel—skin cancer	3.93e-05	0.000557	CcSEcCtD
Dexamethasone—Dermatitis—Docetaxel—skin cancer	3.93e-05	0.000556	CcSEcCtD
Dexamethasone—Headache—Docetaxel—skin cancer	3.9e-05	0.000553	CcSEcCtD
Dexamethasone—Nausea—Docetaxel—skin cancer	3.7e-05	0.000525	CcSEcCtD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	3.16e-05	0.00159	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—MC1R—skin cancer	3.03e-05	0.00153	CbGpPWpGaD
Dexamethasone—CYP1A1—Arachidonic acid metabolism—PTGS2—skin cancer	3.01e-05	0.00152	CbGpPWpGaD
Dexamethasone—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	3.01e-05	0.00152	CbGpPWpGaD
Dexamethasone—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3e-05	0.00151	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—GLI1—skin cancer	2.99e-05	0.00151	CbGpPWpGaD
Dexamethasone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.97e-05	0.0015	CbGpPWpGaD
Dexamethasone—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.95e-05	0.00149	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—CSPG4—skin cancer	2.94e-05	0.00148	CbGpPWpGaD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—CDK4—skin cancer	2.93e-05	0.00148	CbGpPWpGaD
Dexamethasone—NOS2—Spinal Cord Injury—IL6—skin cancer	2.93e-05	0.00147	CbGpPWpGaD
Dexamethasone—ANXA1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.88e-05	0.00145	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—SUFU—skin cancer	2.83e-05	0.00143	CbGpPWpGaD
Dexamethasone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.82e-05	0.00142	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—PLIN2—skin cancer	2.79e-05	0.00141	CbGpPWpGaD
Dexamethasone—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	2.76e-05	0.00139	CbGpPWpGaD
Dexamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	2.68e-05	0.00135	CbGpPWpGaD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—BRAF—skin cancer	2.59e-05	0.00131	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PLIN2—skin cancer	2.55e-05	0.00129	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism—ENO2—skin cancer	2.54e-05	0.00128	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.54e-05	0.00128	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PLIN2—skin cancer	2.53e-05	0.00127	CbGpPWpGaD
Dexamethasone—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.51e-05	0.00126	CbGpPWpGaD
Dexamethasone—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.5e-05	0.00126	CbGpPWpGaD
Dexamethasone—PGR—Signaling by ERBB4—NRAS—skin cancer	2.47e-05	0.00125	CbGpPWpGaD
Dexamethasone—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	2.46e-05	0.00124	CbGpPWpGaD
Dexamethasone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.43e-05	0.00122	CbGpPWpGaD
Dexamethasone—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.4e-05	0.00121	CbGpPWpGaD
Dexamethasone—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	2.39e-05	0.00121	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—CDK4—skin cancer	2.39e-05	0.0012	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.36e-05	0.00119	CbGpPWpGaD
Dexamethasone—NOS2—Disease—SHH—skin cancer	2.33e-05	0.00117	CbGpPWpGaD
Dexamethasone—NOS2—Disease—ENO2—skin cancer	2.33e-05	0.00117	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PTCH2—skin cancer	2.29e-05	0.00116	CbGpPWpGaD
Dexamethasone—NR0B1—Gene Expression—ERCC2—skin cancer	2.27e-05	0.00114	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.25e-05	0.00113	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—CSPG4—skin cancer	2.25e-05	0.00113	CbGpPWpGaD
Dexamethasone—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	2.24e-05	0.00113	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PLIN2—skin cancer	2.24e-05	0.00113	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.24e-05	0.00113	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—SHH—skin cancer	2.16e-05	0.00109	CbGpPWpGaD
Dexamethasone—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.15e-05	0.00108	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—RASA1—skin cancer	2.15e-05	0.00108	CbGpPWpGaD
Dexamethasone—PGR—Signaling by ERBB4—KRAS—skin cancer	2.13e-05	0.00107	CbGpPWpGaD
Dexamethasone—NOS2—Circadian rythm related genes—TP53—skin cancer	2.09e-05	0.00105	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.07e-05	0.00104	CbGpPWpGaD
Dexamethasone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.06e-05	0.00104	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—CSPG4—skin cancer	2.06e-05	0.00104	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—PTCH1—skin cancer	2.05e-05	0.00103	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—SMO—skin cancer	2.05e-05	0.00103	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—CSPG4—skin cancer	2.04e-05	0.00103	CbGpPWpGaD
Dexamethasone—NR3C1—AP-1 transcription factor network—TP53—skin cancer	2.03e-05	0.00102	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—ENO2—skin cancer	2e-05	0.00101	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—PTGER4—skin cancer	2e-05	0.00101	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.98e-05	0.001	CbGpPWpGaD
Dexamethasone—NOS2—Circadian rythm related genes—IL6—skin cancer	1.91e-05	0.000963	CbGpPWpGaD
Dexamethasone—NOS2—Disease—FOXO4—skin cancer	1.9e-05	0.000957	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PLIN2—skin cancer	1.87e-05	0.000943	CbGpPWpGaD
Dexamethasone—NR3C1—AP-1 transcription factor network—IL6—skin cancer	1.86e-05	0.000938	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.84e-05	0.000929	CbGpPWpGaD
Dexamethasone—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.83e-05	0.000922	CbGpPWpGaD
Dexamethasone—PGR—Signaling by ERBB4—HRAS—skin cancer	1.81e-05	0.000912	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—CSPG4—skin cancer	1.81e-05	0.000911	CbGpPWpGaD
Dexamethasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—skin cancer	1.79e-05	0.000903	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—FOXO4—skin cancer	1.76e-05	0.000888	CbGpPWpGaD
Dexamethasone—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	1.74e-05	0.000877	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—GLI2—skin cancer	1.74e-05	0.000876	CbGpPWpGaD
Dexamethasone—NR3C2—Gene Expression—ERCC2—skin cancer	1.73e-05	0.000874	CbGpPWpGaD
Dexamethasone—PGR—Signaling by ERBB4—IL6—skin cancer	1.73e-05	0.000873	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PLIN2—skin cancer	1.69e-05	0.000852	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.68e-05	0.000847	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MC1R—skin cancer	1.66e-05	0.000836	CbGpPWpGaD
Dexamethasone—NR3C1—Glucocorticoid receptor regulatory network—IL6—skin cancer	1.64e-05	0.000826	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—GLI1—skin cancer	1.64e-05	0.000824	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PLIN2—skin cancer	1.63e-05	0.000821	CbGpPWpGaD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.62e-05	0.000818	CbGpPWpGaD
Dexamethasone—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.62e-05	0.000817	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—SUFU—skin cancer	1.55e-05	0.000781	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—ENO2—skin cancer	1.53e-05	0.000771	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—CSPG4—skin cancer	1.51e-05	0.00076	CbGpPWpGaD
Dexamethasone—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	1.5e-05	0.000755	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PLIN2—skin cancer	1.48e-05	0.000747	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism—ERCC2—skin cancer	1.47e-05	0.000743	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PLIN2—skin cancer	1.47e-05	0.00074	CbGpPWpGaD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—KRAS—skin cancer	1.4e-05	0.000707	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—ENO2—skin cancer	1.4e-05	0.000705	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—ENO2—skin cancer	1.39e-05	0.000698	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—CSPG4—skin cancer	1.36e-05	0.000687	CbGpPWpGaD
Dexamethasone—NOS2—Disease—ERCC2—skin cancer	1.35e-05	0.000682	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PLIN2—skin cancer	1.35e-05	0.000678	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—CSPG4—skin cancer	1.31e-05	0.000662	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—NRAS—skin cancer	1.3e-05	0.000657	CbGpPWpGaD
Dexamethasone—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	1.27e-05	0.000642	CbGpPWpGaD
Dexamethasone—NOS2—Disease—TERT—skin cancer	1.27e-05	0.000639	CbGpPWpGaD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—skin cancer	1.25e-05	0.000628	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—ENO2—skin cancer	1.23e-05	0.000619	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.2e-05	0.000603	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—CSPG4—skin cancer	1.19e-05	0.000602	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—CSPG4—skin cancer	1.18e-05	0.000597	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—SHH—skin cancer	1.18e-05	0.000596	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—TERT—skin cancer	1.18e-05	0.000593	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—RASA1—skin cancer	1.17e-05	0.000592	CbGpPWpGaD
Dexamethasone—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	1.17e-05	0.000592	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—ERCC2—skin cancer	1.16e-05	0.000585	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.15e-05	0.00058	CbGpPWpGaD
Dexamethasone—NR3C1—Adipogenesis—IL6—skin cancer	1.13e-05	0.000572	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PLIN2—skin cancer	1.13e-05	0.00057	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—KRAS—skin cancer	1.12e-05	0.000565	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—SMO—skin cancer	1.12e-05	0.000565	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PTCH1—skin cancer	1.12e-05	0.000565	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.09e-05	0.000551	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PTGER4—skin cancer	1.09e-05	0.00055	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CSPG4—skin cancer	1.09e-05	0.000548	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PLIN2—skin cancer	1.09e-05	0.000547	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—CSPG4—skin cancer	1.09e-05	0.000547	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.08e-05	0.000546	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PLIN2—skin cancer	1.06e-05	0.000536	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PLIN2—skin cancer	1.06e-05	0.000535	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—ERCC2—skin cancer	1.06e-05	0.000532	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—ENO2—skin cancer	1.03e-05	0.000517	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—TP53—skin cancer	1.01e-05	0.000511	CbGpPWpGaD
Dexamethasone—NOS2—Disease—BRAF—skin cancer	1e-05	0.000506	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PLIN2—skin cancer	1e-05	0.000505	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—TP53—skin cancer	9.97e-06	0.000502	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling by GPCR—NRAS—skin cancer	9.92e-06	0.0005	CbGpPWpGaD
Dexamethasone—NR3C1—SIDS Susceptibility Pathways—IL6—skin cancer	9.8e-06	0.000494	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—FOXO4—skin cancer	9.64e-06	0.000486	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.61e-06	0.000484	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—HRAS—skin cancer	9.54e-06	0.000481	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—BRAF—skin cancer	9.32e-06	0.00047	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—IL6—skin cancer	9.29e-06	0.000468	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—ENO2—skin cancer	9.27e-06	0.000467	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PLIN2—skin cancer	9.2e-06	0.000463	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CSPG4—skin cancer	9.11e-06	0.000459	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—ENO2—skin cancer	8.93e-06	0.00045	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—ERCC2—skin cancer	8.89e-06	0.000448	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism—PTGS2—skin cancer	8.84e-06	0.000445	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CSPG4—skin cancer	8.76e-06	0.000441	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CSPG4—skin cancer	8.58e-06	0.000432	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CSPG4—skin cancer	8.56e-06	0.000431	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling by GPCR—KRAS—skin cancer	8.54e-06	0.00043	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	8.22e-06	0.000414	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PLIN2—skin cancer	8.21e-06	0.000414	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—ERCC2—skin cancer	8.13e-06	0.000409	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—ENO2—skin cancer	8.12e-06	0.000409	CbGpPWpGaD
Dexamethasone—NOS2—Disease—PTGS2—skin cancer	8.11e-06	0.000409	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CSPG4—skin cancer	8.09e-06	0.000407	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—ENO2—skin cancer	8.05e-06	0.000406	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—ERCC2—skin cancer	8.05e-06	0.000405	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.02e-06	0.000404	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PLIN2—skin cancer	8.01e-06	0.000404	CbGpPWpGaD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	7.77e-06	0.000391	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PLIN2—skin cancer	7.55e-06	0.00038	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PLIN2—skin cancer	7.48e-06	0.000377	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CSPG4—skin cancer	7.41e-06	0.000374	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ENO2—skin cancer	7.39e-06	0.000373	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—SHH—skin cancer	7.39e-06	0.000373	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—ENO2—skin cancer	7.38e-06	0.000372	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling by GPCR—HRAS—skin cancer	7.26e-06	0.000366	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.25e-06	0.000365	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—ERCC2—skin cancer	7.14e-06	0.00036	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.98e-06	0.000352	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—PTGS2—skin cancer	6.96e-06	0.000351	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling by GPCR—IL6—skin cancer	6.94e-06	0.00035	CbGpPWpGaD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.9e-06	0.000348	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CSPG4—skin cancer	6.62e-06	0.000333	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CSPG4—skin cancer	6.46e-06	0.000325	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TERT—skin cancer	6.44e-06	0.000324	CbGpPWpGaD
Dexamethasone—NOS2—Disease—NRAS—skin cancer	6.31e-06	0.000318	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ENO2—skin cancer	6.19e-06	0.000312	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—ERCC2—skin cancer	6.1e-06	0.000308	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CSPG4—skin cancer	6.09e-06	0.000307	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CSPG4—skin cancer	6.03e-06	0.000304	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—FOXO4—skin cancer	6.03e-06	0.000304	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—ERCC2—skin cancer	5.96e-06	0.0003	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ENO2—skin cancer	5.95e-06	0.0003	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—NRAS—skin cancer	5.86e-06	0.000295	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ENO2—skin cancer	5.83e-06	0.000294	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ENO2—skin cancer	5.82e-06	0.000293	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.51e-06	0.000277	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ENO2—skin cancer	5.5e-06	0.000277	CbGpPWpGaD
Dexamethasone—NOS2—Disease—KRAS—skin cancer	5.43e-06	0.000274	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—ERCC2—skin cancer	5.38e-06	0.000271	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—PTGS2—skin cancer	5.33e-06	0.000268	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—ERCC2—skin cancer	5.18e-06	0.000261	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—BRAF—skin cancer	5.1e-06	0.000257	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—KRAS—skin cancer	5.04e-06	0.000254	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ENO2—skin cancer	5.04e-06	0.000254	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PLIN2—skin cancer	4.94e-06	0.000249	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.89e-06	0.000247	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PTGS2—skin cancer	4.87e-06	0.000246	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PTGS2—skin cancer	4.82e-06	0.000243	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—ERCC2—skin cancer	4.72e-06	0.000238	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—ERCC2—skin cancer	4.67e-06	0.000236	CbGpPWpGaD
Dexamethasone—NOS2—Disease—HRAS—skin cancer	4.62e-06	0.000233	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ENO2—skin cancer	4.5e-06	0.000227	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—TP53—skin cancer	4.48e-06	0.000226	CbGpPWpGaD
Dexamethasone—NOS2—Disease—IL6—skin cancer	4.42e-06	0.000223	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ENO2—skin cancer	4.39e-06	0.000221	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.3e-06	0.000217	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ERCC2—skin cancer	4.3e-06	0.000216	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—HRAS—skin cancer	4.29e-06	0.000216	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—ERCC2—skin cancer	4.29e-06	0.000216	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PTGS2—skin cancer	4.28e-06	0.000216	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ENO2—skin cancer	4.14e-06	0.000208	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—IL6—skin cancer	4.1e-06	0.000207	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ENO2—skin cancer	4.1e-06	0.000207	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TERT—skin cancer	4.03e-06	0.000203	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CSPG4—skin cancer	3.98e-06	0.0002	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.94e-06	0.000199	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ERCC2—skin cancer	3.6e-06	0.000181	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PTGS2—skin cancer	3.57e-06	0.00018	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.52e-06	0.000177	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ERCC2—skin cancer	3.46e-06	0.000174	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ERCC2—skin cancer	3.39e-06	0.000171	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ERCC2—skin cancer	3.38e-06	0.00017	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PTGS2—skin cancer	3.23e-06	0.000163	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.21e-06	0.000162	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—NRAS—skin cancer	3.2e-06	0.000161	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ERCC2—skin cancer	3.19e-06	0.000161	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—BRAF—skin cancer	3.19e-06	0.000161	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PTGS2—skin cancer	3.11e-06	0.000157	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ERCC2—skin cancer	2.93e-06	0.000147	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PTGS2—skin cancer	2.83e-06	0.000142	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PTGS2—skin cancer	2.8e-06	0.000141	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—KRAS—skin cancer	2.76e-06	0.000139	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ENO2—skin cancer	2.7e-06	0.000136	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ERCC2—skin cancer	2.61e-06	0.000132	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PTGS2—skin cancer	2.57e-06	0.000129	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ERCC2—skin cancer	2.55e-06	0.000128	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TP53—skin cancer	2.45e-06	0.000123	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ERCC2—skin cancer	2.4e-06	0.000121	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ERCC2—skin cancer	2.38e-06	0.00012	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—HRAS—skin cancer	2.34e-06	0.000118	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—IL6—skin cancer	2.24e-06	0.000113	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PTGS2—skin cancer	2.07e-06	0.000104	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PTGS2—skin cancer	2.03e-06	0.000102	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PTGS2—skin cancer	2.03e-06	0.000102	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NRAS—skin cancer	2e-06	0.000101	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PTGS2—skin cancer	1.91e-06	9.65e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTGS2—skin cancer	1.76e-06	8.84e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—KRAS—skin cancer	1.72e-06	8.69e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ERCC2—skin cancer	1.57e-06	7.92e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTGS2—skin cancer	1.57e-06	7.89e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTGS2—skin cancer	1.53e-06	7.7e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HRAS—skin cancer	1.47e-06	7.39e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTGS2—skin cancer	1.44e-06	7.26e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTGS2—skin cancer	1.43e-06	7.2e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—IL6—skin cancer	1.4e-06	7.07e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTGS2—skin cancer	9.42e-07	4.75e-05	CbGpPWpGaD
